




CANADIAN  
NEUROLOGICAL  
SCIENCES  
FEDERATION  
FÉDÉRATION  
DES SCIENCES  
NEUROLOGIQUES  
DU CANADA

# The Journal

Canadian Journal of Neurological Sciences

VOLUME 36 NUMBER 6 NOVEMBER 2009



*University of Alberta, Edmonton, Alberta. Photos courtesy of Dirk Everaert*

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

*The official Journal of:* The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology


PM 48007777

P 0834



Beyond technology

there's possibility



Over 40 years ago Professor Lars Leksell invented Gamma Knife® surgery, a revolutionary, non-invasive way to perform brain surgery that created new treatment possibilities for patients with inoperable brain cancer. Today, Leksell Gamma Knife® Perfexion™ is the cornerstone of a complete line of stereotactic treatment and radiosurgery solutions that is still creating new possibilities for the most challenging cases of the brain, head & neck, and body.


*Human care makes the future possible*



Elekta Axesse™



Leksell Gamma Knife® Perfexion™




Extend™ program

[www.elekta.com](http://www.elekta.com)

Extend™ requires 510(k) review and is not yet commercially available in the U.S.

<https://doi.org/10.1017/S0317167100117834> Published online by Cambridge University Press



**ELEKTA**  
NEUROSCIENCE

---

THE CANADIAN JOURNAL OF

# Neurological Sciences

---

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

---

VOLUME 36 NUMBER 6 NOVEMBER 2009

## EDITORIALS

- 671** Stroke Care - More Than Just Saving Brain  
*Jessica Simon, Martin J. LaBrie, Shelagh B. Coutts*
- 673** Cost-Effectiveness of Pharmacological Treatment in Vascular Dementia  
*Fadi Massoud*
- 675** Injury Prevention in the Classroom. You Only Get One Brain  
*Charles H. Tator*
- 677** Investigations for Syncope; Role of EEG and the Specialty of the Ordering Physician  
*Manouchehr Javidan*

## REVIEW ARTICLES

- 679** Febrile Seizures: Current Views and Investigations  
*Aylin Y. Reid, Michael A. Galic, G. Campbell Teskey, Quentin J. Pittman*
- 687** Tension-Type Headache in Children: The Cinderella of Headache Disorders!  
*Shashi S. Seshia, Ishaq Abu-Arafeh, Andrew D. Hershey*

## ORIGINAL ARTICLES

- 696** The Metabolic Epicenter of Supratentorial Gliomas: A <sup>1</sup>H-MRSI Study  
*Tejas Sankar, Yevgeniy E. Kuznetsov, Robert W. Ryan, Zografos Caramanos, Samson B. Antel, Douglas L. Arnold, Mark C. Preul*
- 707** Postoperative Surveillance Magnetic Resonance Imaging for Cerebellar Astrocytoma  
*Michael Vassilyadi, Mohammed F. Shamji, Zachary Tataryn, Daniel Keene, Enrique Ventureyra*
- 713** The Cerebellar Dysplasia of Chiari II Malformation as Revealed by Eye Movements  
*Michael S. Salman, Maureen Dennis, James A. Sharpe*

- 725** Seroprevalence of *Chlamydia Pneumoniae* Antibodies in Stroke in Young  
*V.C.S. Srinivasarao Bandaru, D. Babu Boddu, V. Laxmi, M. Neeraja, S. Kaul*
- 731** Evaluating an Organized Palliative Care Approach in Patients with Severe Stroke  
*Dylan P.V. Blacquiere, Gord J. Gubitz, David Dupere, Deborah McLeod, Stephen Phillips*
- 735** Cost-Effectiveness: Cholinesterase Inhibitors and Memantine in Vascular Dementia  
*Camilla L. Wong, Nick Bansback, Philip E. Lee, Aslam H. Anis*
- 740** Contrast Echocardiography and Migraine in Divers with Patent Foramen Ovale  
*Roberto Di Fabio, Elisabetta Giugni, Imerio Angeloni, Nicola Vanacore, Carlo Casali, Alberto Pierallini, Rita Vadalà, Francesco Pierelli*
- 745** Endovascular Therapy of Hypoglossal Canal AVFs Presenting with Orbital Symptoms  
*Vladislav Miropolsky, Leodante B. da Costa, Thomas R. Marotta, Julian Spears*
- 751** Pediatric Traumatic Dural Arteriovenous Fistula  
*Michael Vassilyadi, Naveen Mehrotra, Mohammed F. Shamji, Jean Michaud*
- 757** A Rare Case of Cerebral Cortical Dysplasia with Arterial Vascular Dysplasia  
*Jai Jai Shiva Shankar, Susitna Trina Banerjee, Matthew Hogan, Karel terBrugge, Pierre Lasjaunias, Marlise P. dos Santos*
- 761** Evaluation of ThinkFirst for Kids Injury Prevention Curriculum for Grades 7/8  
*Michael Vassilyadi, Cheryl Duquette, Mohammed F. Shamji, Shari Orders, Simon Dagenais*
- 769** EEG in Suspected Syncope: Do EEGs Ordered by Neurologists Give a Higher Yield?  
*Laurence Poliquin-Lasnier, Fraser G.A. Moore*



---

THE CANADIAN JOURNAL OF

# Neurological Sciences

---

LE JOURNAL CANADIEN DES

# Sciences Neurologiques

---

VOLUME 36 NUMBER 6 NOVEMBER 2009

## NEUROIMAGING HIGHLIGHTS

- 774** Submitted by: Gary L. Gallia, Zev A. Binder, Jacob Schwarz, John L. Moriarity, Jon D. Weingart
- 776** Submitted by: Alim P. Mitha, Forrest D. Hsu, James N. Scott, Bassam M. Addas, Yves Starreveld

## BRIEF COMMUNICATIONS (formerly Case Reports)

- 779** Hypocupremia: An Under Recognized Cause of Subacute Combined Degeneration  
*Irene Y.L. Tan, Lyne Noël de Tilly, Trevor A. Gray*
- 783** An Unusual Presentation of Neurosarcoidosis in an 11-Year-Old Boy  
*V. Scholten, W.M. ten Hove, E.A. Macdonald*
- 787** MRI Changes with Acute Shingles  
*Kathleen Joy Khu, Mark Bernstein*
- 789** Plasma Homocysteine Levels After Acute Stroke and in the Convalescent Phase  
*Susanna Moskau, Alexander Semmler, Birgit Stoffel-Wagner, Michael Linnebank*

## REFLECTIONS


- 791** For Want of the Right Letter the Child Was Lost ... Almost  
*Patrick McDonald*

## CORRESPONDENCE

- 793** Letters to the Editor
- 795** Books Received / Books Reviewed
- 797** Author Index to Volume 36 - 2009
- 800** Subject Index to Volume 36 - 2009
- A-9** Advertisers Index
- A-19** Board of Directors/Committee Chairs
- A-10** Calendar of Events
- A-9, A-20** Classified Ads
- A-7, A-8** Information for Authors
- IBC** CNSF Sponsors

For your patients with CIS or RRMS,

Consider  
Pr **COPAXONE**<sup>®</sup>  
from the start, and  
for the long run.



■ **In RRMS, demonstrated impact on disability and reduction in relapse rates**

- Greater reduction in mean change in EDSS scores vs. placebo over 2 years (COPAXONE<sup>®</sup> -0.05, placebo +0.21; n=251, p=0.023)<sup>††</sup>
- 29% mean reduction in relapse rates at 24 months (COPAXONE<sup>®</sup> 1.19, placebo 1.68; n=251, p=0.007)<sup>††</sup>

■ **In CIS, delayed time to CDMS<sup>‡§</sup>**

- COPAXONE<sup>®</sup> prolonged the time to CDMS by 386 days<sup>§¶</sup> (Placebo 336 days vs. COPAXONE<sup>®</sup> 722 days; n=481; p=0.0005)<sup>†</sup>

■ **Established safety profile**

- Over 13 years of safety data in open-label extension trials<sup>†</sup>
- No recommended monitoring of liver and thyroid function or complete blood count<sup>†</sup>

COPAXONE<sup>®</sup> is indicated for the treatment of ambulatory patients with Relapsing Remitting Multiple Sclerosis (RRMS) to decrease the frequency of clinical exacerbations; to reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans. COPAXONE<sup>®</sup> is indicated for the treatment of patients who have experienced a single demyelinating event, accompanied by abnormal MRI scans and are considered to be at risk of developing Clinically Definite MS (CDMS), after alternative diagnoses are excluded: to delay the onset of definite MS; to decrease the number and volume of active brain lesions and overall disease burden (as identified by MRI scans). The safety and efficacy of COPAXONE<sup>®</sup> in chronic progressive MS have not been established.

In placebo-controlled clinical trials, the most commonly observed adverse events associated with the use of COPAXONE<sup>®</sup> occurring at an incidence of at least 10% and at least 1.5 times higher than in placebo treated patients were: injection site reactions, vasodilatation, rash, dyspnea and chest pain.

\* CIS: Clinically Isolated Syndrome. † Multicenter, double-blind, randomized, placebo-controlled trial in 251 patients with RRMS who were randomized to receive 20 mg/day glatiramer acetate (n=125) or placebo (n=126) subcutaneously. Patients were diagnosed with RRMS by standard criteria, and had at least 2 exacerbations during the 2 years immediately preceding enrollment. Primary outcome measure was the mean number of relapses during treatment. ‡ CDMS: Clinically Definite Multiple Sclerosis. § Delay to CDMS is based on the 25<sup>th</sup> percentile; Kaplan-Meier estimates. ¶ Multicenter, randomized, double-blind, placebo-controlled, parallel group study in 481 patients for up to three years (glatiramer acetate 20 mg/day; n=243; placebo: n=238) was performed in patients with a well-defined, single, unifocal neurological presentation and MRI features suggestive of MS (at least two cerebral lesions on T2-weighted MRI). A total of 25% of glatiramer acetate patients, and 43% of placebo patients converted to CDMS in an average duration of treatment of 2.4 years.



COPAXONE<sup>®</sup> is a registered trademark of Teva Pharmaceutical Industries Ltd. and is used under licence. TEVA and the design version thereof are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under licence. ©2009 Teva Neuroscience G.P. - S.E.N.C. Montreal, Quebec H3A 3L4  
Reference: 1. COPAXONE<sup>®</sup> (glatiramer acetate injection) Product Monograph. TEVA Neuroscience. April 2009.



**COPAXONE**<sup>®</sup>  
(glatiramer acetate injection)

Treat from the start. Treat for the long run.





THE CANADIAN JOURNAL OF  
**Neurological Sciences**  
LE JOURNAL CANADIEN DES  
**Sciences Neurologiques**

VOLUME 36 NUMBER 6 NOVEMBER 2009

**Editor-in-Chief/Rédacteur en chef**

G. Bryan Young LONDON, ON

**Associate Editors/Rédacteurs associés**

J. Max Findlay EDMONTON, AB  
Michael Shevell MONTREAL, QC  
Timothy J. Benstead HALIFAX, NS  
Mike Poulter LONDON, ON  
Serge Gauthier VERDUN, QC  
Mandar Jog LONDON, ON

**Past Editors/Anciens rédacteurs en chef**

Douglas W. Zochodne CALGARY, AB  
James A. Sharpe TORONTO, ON  
Robert G. Lee CALGARY, AB  
Robert T. Ross WINNIPEG, MB  
(Emeritus Editor, Founding Editor)

**Editorial Board/Conseil d'éditorial**

Jorge Burneo LONDON, ON  
Richard Desbiens QUEBEC CITY, QC  
David Fortin SHERBROOKE, QC  
Mark Hamilton CALGARY, AB  
Robert Hammond LONDON, ON  
Hans-Peter Hartung DUSSELDORF, GERMANY  
Michael Hill CALGARY, AB  
Alan C. Jackson WINNIPEG, MB  
Daniel Keene OTTAWA, ON  
Terence Myles CALGARY, AB  
James Perry TORONTO, ON  
Oksana Suchowersky CALGARY, AB  
Brian Toyota VANCOUVER, BC  
Brian Weinschenker ROCHESTER, MN, USA  
Samuel Wiebe CALGARY, AB  
Elaine Wirrell ROCHESTER, MN, USA

**SECTION EDITORS/CONSEIL DE RÉDACTION**

**Neuroimaging Highlight/Neuroimagerie**

Richard Farb TORONTO, ON  
David Pelz LONDON, ON

**Neuropathological Conference/Conférence sur la neuropathologie**

Robert Hammond LONDON, ON

**Book Review/Critiques de livres**

Andrew Kirk SASKATOON, SK

**Critically Appraised Topic Summaries (CATS)**

Jorge Burneo LONDON, ON  
Mary Jenkins LONDON, ON

**Editorial Review Board/Conseil de Revue d'éditorial**

Donald Brunet KINGSTON, ON  
Lionel Carmant MONTREAL, QC  
Colin Chalk MONTREAL, QC  
K. Ming Chan EDMONTON, AB  
Robert Chen TORONTO, ON  
Mary Connolly VANCOUVER, BC  
Joseph Dooley HALIFAX, NS  
Daryl Fournay SASKATOON, SK  
Hannah Glass SAN FRANCISCO, CA, USA  
Alan Goodridge ST. JOHN'S, NL  
Ian Grant HALIFAX, NS  
Alan Guberman OTTAWA, ON  
John Hurlbert CALGARY, AB  
Manouchehr Javidan VANCOUVER, BC  
Patrick McDonald WINNIPEG, MB  
Martin McKeown VANCOUVER, BC  
Joseph Megyesi LONDON, ON  
Vivek Mehta EDMONTON, AB  
Steven Miller VANCOUVER, BC  
Neelan Pillay CALGARY, AB  
Christopher Power EDMONTON, AB  
Alex Rajput SASKATOON, SK  
Jean Raymond MONTREAL, QC  
Gary Redekop VANCOUVER, BC  
Mark Sadler HALIFAX, NS  
Harvey Sarnat CALGARY, AB  
John Stewart VANCOUVER, BC  
Jeanne Teitelbaum MONTREAL, QC  
Eve Tsai OTTAWA, ON  
Shannon Venance LONDON, ON  
Matt Wheatley EDMONTON, AB  
Jerome Yager EDMONTON, AB

**Journal Staff - Calgary, AB**

Dan Morin, *Chief Executive Officer*  
Maggie McCallion, *Designer/Production Coordinator*  
Cindy Leschyshyn, *Editorial Coordinator*

**Advertising representative/Représentant de publicité:**

Brett Windle  
*Corporate Development Coordinator*  
Tel (403) 229-9575 Fax (403) 229-1661  
E-mail: brett-windle@cnsfederation.org

**Printer/Imprimeur:**

Unicom Graphics, 4501 Manitoba Road SE  
Calgary, Alberta T2G 4B9

**The official journal of / La Revue officielle de:**

**The Canadian Neurological Society  
La Société Canadienne de Neurologie**  
**The Canadian Neurosurgical Society  
La Société Canadienne de Neurochirurgie**  
**The Canadian Society of Clinical Neurophysiologists  
La Société Canadienne de Neurophysiologie Clinique**  
**The Canadian Association of Child Neurology  
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:  
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situ en permanence à:  
7015 Macleod Trail SW, Suite 709, Calgary AB, Canada T2H 2K6.


The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See [www.cjns.org](http://www.cjns.org) for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: [journal@cjns.org](mailto:journal@cjns.org); Web: [www.cjns.org](http://www.cjns.org)  
COPYRIGHT © 2009 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under Publications Mail Agreement no: 40007777; PAP Registration no: 09824. Postage paid at Calgary, Alberta. This journal is indexed by *AbHyg, AgBio, BIOBASE, BioAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerptMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsychInfo, React, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCPrem.*

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel pour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir [www.cjns.org](http://www.cjns.org) pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail [journal@cjns.org](mailto:journal@cjns.org); Web: [www.cjns.org](http://www.cjns.org). DROITS D'AUTEUR © 2009: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Posté sous poste-publications: numéro de convention: 40007777; numéro d'enregistrement PAP 09824. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans *AbHyg, AgBio, BIOBASE, BioAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerptMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsychInfo, React, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCPrem.*



We acknowledge the assistance of the Government of Canada through the Publications Assistance Program towards our mailing costs.





CANADIAN  
NEUROLOGICAL  
SCIENCES  
FEDERATION  
FÉDÉRATION  
DES SCIENCES  
NEUROLOGIQUES  
DU CANADA



*Thank you for joining us at this years  
Congress and we look forward to seeing you  
at our next Congress in Quebec City!*

**SPECTACULAR QUEBEC CITY  
A WHOLE NEW EXPERIENCE**

Some travel destinations just seize the imagination. Their beauty is breathtaking. They evoke wonder and excitement. They are vibrant and alive. They are warm and welcoming. But few do it all as effortlessly as naturally as Quebec, the unique walled city on the St. Lawrence River. No other destination in the world offers Quebec’s compelling mix of features and attractions.

**Canadian Neurological Sciences Federation**

**45th Annual Congress**

**Quebec City, Quebec June 8-11, 2010**

**GOURMET  
QUEBEC CITY**

Quebecers love fine food - and it shows. Every meal in Quebec City is truly a taste sensation. Although Quebec City and its surrounding region are often referred to as North America’s fine dining capital, they would also be called its casual dining capital, its sidewalk cafe capital, its bistro capital, its wine and cheese capital...In fact, food in Quebec City is one of the great pleasures of life - and one of the best reasons for travelling to the city and area time and again!



# Fibromyalgia pain is real. And so is treatment with LYRICA.



## LYRICA is the first treatment indicated in Canada for the management of pain associated with fibromyalgia in adults

- LYRICA is proven to manage the pain associated with fibromyalgia<sup>1</sup>
- LYRICA has been demonstrated to significantly improve pain-related sleep difficulties<sup>2</sup>
  - LYRICA reduced overall MOS-Sleep Scale scores significantly more from baseline versus placebo (LYRICA 300 mg/day -19.1 ( $p=0.0174$ ), LYRICA 450 mg/day -20.41 ( $p=0.0026$ ), and LYRICA 600 mg/day -19.49 ( $p=0.0101$ ) vs -14.29 for placebo)<sup>2\*</sup>

The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

The most commonly observed dose-related adverse events in LYRICA-treated patients were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly reported ( $\geq 5\%$  and twice the rate of that seen in placebo) treatment-related adverse events were: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). Adverse events were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 20% and 11%. There was a

dose-dependent increase in rate of discontinuation due to adverse events.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

**Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.**

See Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

**References:** 1. LYRICA Product Monograph. Pfizer Canada Inc., March 2009. 2. Mease PJ *et al.* A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. *J Rheumatol* 2008;35:502-14.

\* A multicenter, double-blind, 13-week, randomized trial. 748 patients who met the ACR criteria for fibromyalgia and who had an average mean pain score of  $\geq 4$  on an 11-point numeric rating scale (NRS) during the baseline assessment were randomized to LYRICA 300 mg/day ( $n=185$ ), 450 mg/day ( $n=183$ ), 600 mg/day ( $n=190$ ), or placebo ( $n=190$ ). Patients were allowed to take acetaminophen up to 4 g/day as needed for pain relief. The number of completers was: LYRICA 300 mg/day ( $n=123$ ), 450 mg/day ( $n=121$ ), 600 mg/day ( $n=111$ ), or placebo ( $n=130$ ). The primary endpoint was the reduction in endpoint mean pain scores (mean of the last 7 daily pain scores while on study medication). Pain-related sleep difficulties were assessed using the Medical Outcomes Study-Sleep Scale (MOS-SS), a scale that runs from 0-100. Mean baseline MOS-SS score for overall sleep problem index was 65.0.



Working together for a healthier world™

© 2009  
Pfizer Canada Inc.  
Kirkland, Quebec  
H9J 2M5

™ Pfizer Inc, used under license  
LYRICA® C.P. Pharmaceuticals International  
C.V., owner/Pfizer Canada Inc., licensee



See prescribing summary on page A-17, A-18